| Results of the 2015 Questionnaire Survey of the Korean Retina Society: Current Trends in the Treatment of Vitreoretinal Diseases. |
|
Joo Yong Lee, Byung Gil Moon, Min Kim, Joo Eun Lee, Kyu Hyung Park, Si Dong Kim |
1Department of Ophthalmology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
2Department of Ophthalmology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Korea.
3Department of Ophthalmology, Haeundae Paik Hospital, Inje University College of Medicine, Busan, Korea.
4Department of Ophthalmology, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
5Department of Ophthalmology, Daegu Catholic University Medical Center, Catholic University of Daegu School of Medicine, Daegu, Korea. sdkim1@cu.ac.kr |
| 2015년 한국망막학회 회원의 유리체 망막 질환에 대한 설문 조사: 유리체 망막 질환 진료와 치료의 최근 경향 |
|
이주용1⋅문병길1⋅김 민2⋅이주은3⋅박규형4⋅김시동5 |
|
울산대학교 의과대학 서울아산병원 안과학교실1, 연세대학교 의과대학 강남세브란스병원 안과학교실2, 인제대학교 의과대학 해운대백병원 안과학교실3, 서울대학교 의과대학 분당서울대학교병원 안과학교실4, 대구가톨릭대학교 의과대학 대구가톨릭대학교병원 안과학교실5 |
|
|
| Abstract |
PURPOSE
To report the results of the 2015 questionnaire survey of current trends and practice patterns in the treatment of vitreoretinal diseases, which was conducted by the Korean Retina Society (KRS). METHODS: In October 2015, members of the KRS participated in a survey of current trends and practice patterns in the treatment of vitreoretinal diseases. This survey was comprised of 68 multiple choice and dichotomy questions. RESULTS: One hundred eleven (41%) members participated in this survey. Most respondents (42%) had begun their vitreoretinal subspecialty ≤7 years previously, 32% had practiced for 8-15 years, and 26% for 16 years or more. The preferred primary treatment for newly diagnosed wet-type age-related macular degeneration was ranibizumab or aflibercept, and most clinicians (68%) favored a pro re nata regimen. Seventy percent of respondents treated injection-related endophthalmitis using a combination of immediate vitrectomy and intravitreal antibiotic injection. Bevacizumab was the most commonly (78-87%) preferred first-line therapy for macular edema (ME) secondary to central retinal vein occlusion or branch retinal vein occlusion. When ME did not respond to anti-vascular endothelial growth factor treatment, most respondents (91%) switched patients to dexamethasone implant or triamcinolone acetonide. Eighty-four percent of the respondents performed scleral buckling during retinal detachment surgery in fewer than 40% of cases. Also, most respondents (96%) prescribed an antibiotic eye drop after, or before and after intravitreal drug injection. CONCLUSIONS: This survey reflected the recent trends and practice patterns in the treatment of vitreoretinal diseases in Korea. |
| Key Words:
Korean Retina Society;Practice patterns;Survey;Trends;Vitreoretinal disease |
|
PDF Links
Full text via DOI
Download Citation
